Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-04-25

Clinical Trial Update: BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in Subjects With Pre-Diabetes [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating BTI320 (SUGARDOWN) for reducing post-prandial hyperglycemia in people with prediabetes; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BTI320 (SUGARDOWN) (BTI-320)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Pre-Diabetes | Phase 2 | Status: COMPLETED | Results posted: 2017-04-25